A couple reasons to control your enthusiasm. First, tweets of this sort are easily faked, and even when supported they miss important details (I got majorly jerked around by one of these reporting results on a competitive drug to the one Intermune had. The tweet actually got the flavor of the result right, but missed a high incidence of annoying side effects--in context, very important). Second: many analysts are already imputing a lot of value to the IDO inhibitor program; more even than to Baricitinib.
On the positive side, this was one of the programs where scuttlebutt had it that a sufficiently good collection of phase 2 results might lead to approval without a full registration trial.
Can anybody conform whether this was old or new. From Cowen's analysis
"“Meanwhile, we view the early efficacy data from the epacadostat + Keytruda combination as highly promising. Although the numbers are small, an objective response rate of 57% (4/7) and disease control rate of 100% (7/7) are above what might be expected for any single agent anti-PD1 therapy"